Vertex Pharmaceuticals VRTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 344.9%+0.2pp | 344.7%-0.9pp | 344.5%-2.1pp | 344.4%-4.0pp | 344.7%-5.1pp | |
| Returns | ||||||
| Return on invested capital | 103.9%+112pp | 71.8%+44.5pp | 46.9%-13.0pp | 20%-69.2pp | -8.5%-128pp | |
| Efficiency | ||||||
| Asset turnover | 2×+0.1× | 2×0.0× | 2×0.0× | 2×0.0× | 2×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.8×+0.5× | 10.4×-0.8× | 10.2×-2.3× | 10.3×-3.8× | 10.3×-5.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×0.0× | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.2× | 0.4×+0.2× | |
| Net debt / EBITDA | -3×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $281.46+15.2% | $269.49+7.0% | $260.77+2.0% | $253.43-2.2% | $244.33-6.5% | |
| Valuation | ||||||
| Market capitalization | $444.5B-5.3% | $455.56B+0.6% | $444.24B-2.1% | $463.87B+9.5% | $469.26B+19.3% | |
| Price / sales | 37.6×-6.1× | 39.5×-3.5× | 39.3×-4.9× | 42×-0.2× | 43.6×+3.6× | |
| Price / book | 24.6×-5.2× | 26.2×-1.8× | 26.4×-1.3× | 28.3×+2.9× | 29.7×+6.7× | |
| EV / EBITDA | 97.1×— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's profit margins?
- Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
- Where do Vertex Pharmaceuticals's ratios come from?
- Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
